Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH

Update Il y a 4 ans
Reference: NCT02552381

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of the study is to assess the fibrin structure marker in the plasma of cancer patients, treated or not treated with LMWH at prophylactic or therapeutic doses, in order to determine the venous thromboembolic risk. The occurrence of thromboembolic events in patients without treatment and in patients under LMWH treatment will be recorded, depending on the location and type of cancer, metastases, and treatment of cancer.


Inclusion criteria

  • malignant tumor

Links